<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00406094</url>
  </required_header>
  <id_info>
    <org_study_id>NARES</org_study_id>
    <nct_id>NCT00406094</nct_id>
  </id_info>
  <brief_title>Singulair Use in Non-Allergic Rhinitis Eosinophil Syndrome (NARES)</brief_title>
  <official_title>The Evaluation of Singulair for the Treatment of Non-Allergic Rhinitis Eosinophil Syndrome (NARES)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bernstein, Jonathan A., M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bernstein, Jonathan A., M.D.</source>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine if patients with NARES treated with montelukast
      (Singulair) will have improved nasal symptom scores and reduced nasal eosinophils.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will receive either montelukast or placebo in the treatment of NARES. 4 visits will
      be conducted over 12 weeks. A history and physical will be performed at the beginning of the
      trial and at the end. Skin testing will be done at Visit 1. Nasal smears and lavages will be
      performed at every visit. Patients will be compensated for time and travel.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2006</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine whether montelukast is more effective than placebo at reducing the number of nasal eosinophils associated with NARES</measure>
    <time_frame>December 2008</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine whether montelukast is more effective than placebo at reducing nasal symptom scores</measure>
    <time_frame>December 2008</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Rhinitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>montelukast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>montelukast</intervention_name>
    <description>10mg</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Singulair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 - 65 years

          -  Diagnosed with NARES

        Exclusion Criteria:

          -  Smokers, exposed to passive smoke

          -  Diagnosis of seasonal allergic rhinitis (SAR), perennial allergic rhinitis (PAR), or
             vasomotor rhinitis (VMR)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan A Bernstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bernstein Allergy Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jonathan A Bernstein, MD</last_name>
    <phone>513-931-0775</phone>
    <email>bernsteincrc@fuse.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bernstein Allergy Group</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan A Bernstein, MD</last_name>
      <phone>513-931-0775</phone>
      <email>bernsteincrc@fuse.net</email>
    </contact>
    <investigator>
      <last_name>Jonathan A Bernstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2006</study_first_submitted>
  <study_first_submitted_qc>November 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2006</study_first_posted>
  <last_update_submitted>January 15, 2009</last_update_submitted>
  <last_update_submitted_qc>January 15, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2009</last_update_posted>
  <responsible_party>
    <name_title>Jonathan A. Bernstein, MD</name_title>
    <organization>Bernstein Clinical Research Center</organization>
  </responsible_party>
  <keyword>NARES</keyword>
  <keyword>eosinophils</keyword>
  <keyword>nasal symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Common Cold</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 30, 2014</submitted>
    <returned>November 4, 2014</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

